dromlakhani Select CPP treatment strategy
STEP 1 — Gather Information
Collect history of hydrocephalus, tumors near hypothalamus/pituitary, hypothalamic–pituitary radiation exposure, and prior gonadotoxic therapy. Assess clinical pubertal signs (breast development in females, testicular volume not sole indicator in males). Obtain serum testosterone and LH levels before 10:00 AM, and consider Tanner staging, estradiol, and uterine length by ultrasound if needed.
STEP 2 — Rule In / Rule Out
If clinical evidence of pubertal onset before age 8 in girls or 9 in boys is present with elevated LH/FSH or sex steroids consistent with central activation, rule in CPP; otherwise rule out CPP.
STEP 3 — Classify or Stratify
Classify CPP patients as those with concomitant growth hormone deficiency (GHD) versus those without GHD, as this influences whether combined GnRHa and GH therapy is indicated.
STEP 4 — Decide
For confirmed CPP, initiate GnRHa therapy (e.g., leuprolide 11.25 mg IM monthly or equivalent) following noncancer protocols; if GHD is also present, add GH treatment per guideline; monitor LH suppression, Tanner progression, and height velocity every 3–6 months.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on testicular volume alone to assess puberty in males with gonadotoxic therapy; avoid missing CPP due to gonadotropin elevation from primary gonadal injury; do not delay treatment based solely on age <8 years without confirming central activation; watch for pseudotumor cerebri or scoliosis exacerbation during GnRHa therapy.
Concrete Clinical Example
A 7‑year‑old female survivor of craniopharyngioma treated with surgery and 18 Gy cranial radiation presents with Tanner stage 2 breast development, LH 5 IU/L, estradiol 20 pg/mL, and normal GH testing. CPP is ruled in, GHD absent. Start leuprolide 11.25 mg IM monthly; after 6 months LH <0.2 IU/L and breast Tanner stage unchanged, continue therapy until appropriate age for spontaneous puberty.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, 10.1210/jc.2018-01175